Kornimate/medical-research-clean huggingface dataset:
redial: a telephone brief intervention for injured emergency department patients

Conditions: Alcohol Drinking

Summary: the goal of this study is to reduce impaired driving, risky driving and alcohol-related negative consequences among injured emergency department (ed) patients through a telephone brief intervention. this study will allow researchers to test a novel method of brief intervention that has the potential to be convenient and efficient mechanism to deliver an intervention to an at-risk population. eligible patients will be consented in the ed, will receive an assessment and then will be randomized into one of two conditions: 1) telephone brief intervention or 2) a comparison control group with a home safety educational program. the participant will also receive an appointment for an initial telephone call. both conditions will be provided over three telephone sessions: the initial call (immediately following randomization) and two booster calls at 2 weeks and 6 weeks after randomization. participants will provide information about their alcohol use, alcohol-related injuries, impaired driving, and other driving related negative consequences at 4, 8, and 12 months post-randomization.


Eligibility criteria:
inclusion criteria: * english or spanish speaking * age greater than 17 years * assist score \>=11 * injured emergency department patient at time of consent exclusion criteria: * medically unable to give consent * not english or spanish speaking * homeless * cannot be contacted by telephone

Keywords: alcohol brief intervention injuries
impact of resident participation in post-icu follow up clinic

Conditions: Professional Burnout

Summary: this study is being conducted to describe the impact of a meeting between patients that were admitted to the intensive care unit (icu) and a provider that cared for the patients during the period of critical illness. the study team is aiming to describe the effect this meeting has on the physician that previously cared for the patient. the study team hypothesizes that facilitating involvement in post-icu clinic and creating longitudinal relationships between providers of critical care and survivors of critical illness will have positive effects on trainees, both in professional fulfillment and burnout scores and in perceptions of critical care.

physicians and patients that had been cared for in the icu will be enrolled in this project. residents that are recruited will be randomized to the encounter group or the control group.

Eligibility criteria:
inclusion criteria for patients: - must be eligible for post icu longitudinal survivor experience (pulse) clinic follow up and/or have received referral to clinic inclusion criteria for residents: * must have completed at least one 2-week rotation in the medical icu at the university of michigan * must have cared for an enrolled patient in the study exclusion criteria for patients: - died during icu stay exclusion criteria for residents: - provided only "cross-cover" for the patient.

Keywords: perceptions of critical care professional fulfillment.
a study of milvexian versus apixaban in participants with atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (cns) systemic embolism.


Eligibility criteria:
inclusion criteria: * minimum age of 18 years * medically stable and appropriate for chronic antithrombotic treatment * atrial fibrillation eligible to receive anticoagulation * participant must satisfy one or both of the following categories of risk factors (a or b): a) one or more of the following risk factors: i) age greater than or equal to 75 years, ii) history of any type of stroke including symptomatic stroke of any kind. b) two or more of the following risk factors: i) age between 65 and 74 years, ii) hypertension, iii) diabetes mellitus, iv) atherosclerotic vascular disease, v) heart failure exclusion criteria: * hemodynamically significant valve disease or those with valve disease that will potentially require surgical valve replacement during the study * any condition other than af that requires chronic anticoagulation
a pilot study to evaluate a revised method of assessing food in a commercial weight management program format

Conditions: Obesity; Overweight

Summary: this study will provide data on two systems for assigning point values to food choices in a diet plan. the primary purpose of this study is to compare the effectiveness of the two systems with regard to changes in body weight.


Eligibility criteria:
inclusion criteria: * male or female 25-65 years of age inclusive * body mass index (bmi) 27.0 -35.0 inclusive. * not currently taking a prescription medication for weight loss (e.g. orlistat (xenical), sibutramine (meridia), phentermine). * not currently taking any over-the-counter weight loss medications or supplement(s). * not currently enrolled in commercial weight loss program (e.g. jenny craig, weight watchers) or self-help group (e.g. tops, overeaters anonymous). * willing and able to commit to regular physical activity (e.g. walking) five days per week as required by study protocol. * willing to keep and turn in a daily log/compliance book at the times required by study protocol. * willingness and ability to make all scheduled appointments at musc as required by study protocol. * willingness to make weekly meetings at musc. exclusion criteria: * history of thyroid disease, but not taking medication, or medication dosage changed one or more times over last 6 months. history of thyroid disease and on a stable dose of prescription medication for 6 months or longer is acceptable. * diagnosed with type i or type ii diabetes or glucose intolerance, or use of anti-diabetic medications * history of a surgical procedure for weight loss at any time (e.g. gastroplasty, gastric by-pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve). * history of major surgery within three months of enrollment. * history of heart problems (e.g. angina, bypass surgery, mi, etc.) within three months prior to enrollment. * presence of implanted cardiac defibrillator or pacemaker. * uncontrolled hypertension/high blood pressure. * orthopedic limitations that would interfere with ability to engage in regular physical activity. * gastrointestinal disorders including chronic malabsorptive conditions, peptic ulcer disease, crohn's disease, chronic diarrhea or active gallbladder disease. * history or presence of cancer. persons with successfully resected basal cell carcinoma of the skin may be enrolled if treatment completed more than 6 months prior to enrollment. * history of clinically diagnosed eating disorders including anorexia nervosa or bulimia nervosa. * women who are pregnant, lactating , trying to become pregnant or unwilling to use an effective means of birth control. * participation in another clinical trial within 30 days prior to enrollment. * weight loss of more than 5 pounds for any reason over the 30 days prior to enrollment. * taking any psychotropic medicine known to influence weight or weight loss

Keywords: weight loss diet obesity
apatinib with albumin-bound paclitaxel in patients with platinum-resistant recurrent ovarian cancer

Conditions: Ovarian Cancer

Summary: the study was designed to evaluate the efficacy and safety of apatinib with albumin-bound paclitaxel in patients with platinum-resistant recurrent ovarian cancer.

the study is an open, one-arm, prospec will collect 35 patients with platinum-resistant recurrent ovarian cancer treated with apatinib with albumin-bound paclitaxel from 2019 to 2020 in henan cancer hospital.antiangiogenic treatments have been implicated to play a major role in ovarian cancer (oc). apatinib, a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (vegfr2), in combination with weekly paclitaxel, may improve clinical outcomes compared with apatinib or paclitaxel alone in patients with refractory or platinum-resistant ovarian cancer.

Eligibility criteria:
inclusion criteria: 1. female, age ≥18 years and ≤70 years, signed informed consent. 2. platinum resistant ovarian cancer (defined as relapsing within 6 months after the last administration of platinum-based chemotherapy) or platinum refractory ovarian cancer (defined as progressing while on a platinum-based chemotherapy). 3. at least treated with one line of platinum-based chemotherapy. 4. imaging confirmed diagnosis of progression occurred after the last treatment before enrollment. 5. histologically or pathologically confirmed diagnosis of ovarian cancer as primary tumor. 6. measurable disease according to response evaluation criteria in solid tumors (recist) 1.1 version. 7. eastern cooperative oncology group (ecog) performance status 0-2. 8. patients must have a life expectancy of at least 3 months. 9. patients must have adequate organ function as defined by the following criteria: 10. white blood cell count ≥ 3 x 10\^9/l, absolute neutrophil count (anc) (≥ 1.5 x 10\^9/l), hemoglobin of ≥ 80 g/l, platelets ≥ 70 x 10\^9/l, total bilirubin ≤ 1 x upper limit of normal (uln), ast and alt ≤ 2 x uln, serum creatinine ≤ 1 x uln. exclusion criteria: * 1.had prior exposure to apatinib or has known allegies to any of the excipients. 2.patients with trauma, surgical history, gastrointestinal bleeding, and melena within 1 month prior to treatment. 3.inadequately controlled hypertension. 4.history of abdominal fistula or gastrointestinal perforation within 28 days prior to day 1. 5.imaging studies suggest that patients with tumors invading important blood vessels. 6.symptomatic central nervous system (cns) metastasis. 7.history of myocardial infarction, or unstable angina, or new york heart association (nyha) grade iii-iv within 6 months prior to day 1.
data analysis for drug repurposing for effective alzheimer's medicines (dream) - salbutamol vs long-acting muscarinic antagonists

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study aims to evaluate the comparative risk of dementia/alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

this is a non-randomized, non-interventional study that is part of the dream study of brigham and women's hospital. dream is led by dr. madhav thambisetty, md, phd, chief of the clinical and translational neuroscience section, laboratory of behavioral neuroscience, national institute on aging (nia) intramural research program. this study aims to evaluate the comparative risk of dementia/alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.

Eligibility criteria:
please see https://docs.google.com/spreadsheets/d/1j53_nbnevqik4ps5a9pzovuhm1mwhcrz3davi0y8no8/edit?usp=sharing or appendix a (https://drive.google.com/file/d/1uc_g8tj1ujojbas1p1gfayfzy7hw7xmq/view?usp=sharing) for full code and algorithm definitions. medicare timeframe: 2008 to 2018 (end of data availability). inclusion criteria: * 1. aged \>/= 65 years on the index date * 2. no prior use of salbutamol and long-acting muscarinic antagonists (lama) anytime prior to cohort entry date * 3. enrollment in medicare part a, b, and d with no hmo coverage for 365 days prior to and including cohort entry date * 4. at least two claims with copd diagnosis measured 365 days prior to drug initiation exclusion criteria: * 1. prior history of dementia measured anytime prior to cohort entry date * 2. prior history of nursing home admission in the 365 days prior to the cohort entry date
evaluation of the occurrence of lipoatrophy in hiv-1 infected naive patients

Conditions: HIV Infections; HIV-Associated Lipodystrophy Syndrome

Summary: the aim of this randomized study is to compare the occurrence of lipoatrophy in hiv-1 infected, naive patients receiving either a nucleoside reverse transcriptase inhibitor (nrti)-sparing antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor (nnrti) and boosted protease inhibitor (pi), or a standard antiretroviral therapy with 2 nrti plus either pi or nnrti. lipoatrophy is evaluated by measurement of fat volume by computed tomography (ct)-scan and dexa (dual energy x-ray absorptiometry).

the study compare the rate of occurrence of lipoatrophy in arvnaive hiv-1 infected patients receiving either a nrti-sparing antiretroviral therapy with nrti and boosted pi,or a standard antiretroviral therapy with 2 nrti plus pi or nnrti. patients were randomized (2:1:1) to either pi+nnrti (gp1) or standard therapy, 2nrti+ either pi (gp2) or + nnrti (gp3). the study-treatment were lopinavir/r 100/400mg bid or indinavir/r 100/400mg bid for pi-class, for nnrti-class, efavirenz or nevirapine and all nrtis except d4t and ddc at usual dosage. lipoatrophy is evaluated by evolution of subcutaneous fat in the limbs measured by dexa (dual energy x-ray absorptiometry)and ct-scan of the thighs between baseline and w96.

Eligibility criteria:
inclusion criteria: * confirmed hiv-1-infected diagnosis * naive of antiretroviral treatment * plasma viral load (vl) over 5000 copies/ ml * cd4 count below or equal to 350/mm3 or cd4 over 350/mm3 and vl over or equal to 100 000 copies/ml * written, informed consent after approval by the local human research ethics committee exclusion criteria: * acute opportunistic infection * pregnancy or breast feeding * cytotoxic systemic chemotherapy except for kaposi sarcoma * patient infected with b or c hepatitis requiring specific treatment at the beginning of the study * polynuclear neutrophils below 750/mm3 * hemoglobin below 8 g/dl * platelets below 20 000/mm3 * creatinine level over 1.5 (upper normal) un * asat, alat, bilirubin level over 3 un

Keywords: hiv protease inhibitors hiv-associated lipodystrophy syndrome hiv infections
a study of the prevalence of headache in epileptic patients

Conditions: Epilepsy

Summary: the purpose of this study is to investigate the prevalence, characteristics and classification of headaches in epileptic patients.

headache is often ignored as a symptom of epileptic seizures. the purpose of this survey is to investigate the prevalence, characteristics and classification of seizure-associated headaches and non-seizure-associated headaches in epileptic patients in korea, according the criteria of the international headache society 2004. in this survey, 577 consecutive patients with a recent diagnosis of epilepsy are interviewed by questionnaire about headaches associated with epileptic seizures. it involves questions about headache in general, localization, severity, duration and frequency, as well as headache associated with seizures, and about patient's family history. this observational study does not involve the administration of any drugs.

Eligibility criteria:
inclusion criteria: * patients with a recent diagnosis epilepsy * able to describe their symptoms by themselves * have had at least 2 episodes of seizures during the previous year * have had at least 1 headache during the previous year exclusion criteria: * well-controlled epileptic patients taking anti-epileptic medications

Keywords: epilepsy headache seizure
fmri in cardiac arrest with uncertain prognosis

Conditions: Cardiac Arrest

Summary: the goal of this observational study is to determine whether specific advanced mri measures are associated with functional outcomes in patients who are comatose after cardiac arrest. the main question\[s\] it aims to answer are: aim 1: determine if stimulus-based functional mri (fmri)-measured activations are independently associated with favorable neurological outcomes after cardiac arrest aim 2: determine if resting state functional mri (rs-fmri)-measured functional network connectivity is independently associated with favorable neurological outcomes after cardiac arrest. aim 3: determine if diffusion tensor imaging (dti)-measured white matter integrity is associated with favorable neurological outcomes after cardiac arrest. participants will undergo advanced mri sequences at time of clinical mri, and will be followed for 6 months post-arrest.

our goal here is to determine whether advanced functional mri and dti sequences add actionable prognostic information relative to standard clinical mri in patients who remain comatose after cardiac arrest. we plan the following specific analyses: aim 1: we will use logistic regression to measure the association between our primary outcome and fmri bold response to (a) passive language stimuli, (b) motor imagery or (c) passive sensory stimuli, in a model with age, glasgow coma scale (gcs) score at time of mri, and presence of anoxic injury on clinical diffusion weighted mri. aim 2: we will use logistic regression to measure the association between our primary outcome and default mode network resting state functional connectivity, in a model with age, glasgow coma scale (gcs) score at time of mri, and presence of anoxic injury on clinical diffusion weighted mri. aim 3: we will use logistic regression to measure the association between our primary outcome and diffusion tensor imaging (dti)-measured mean white matter fractional anisotropy, in a model with age, glasgow coma scale (gcs) score at time of mri, and presence of anoxic injury on clinical diffusion weighted mri.

Eligibility criteria:
inclusion criteria: * survive of an in or out of hospital cardiac arrest exclusion criteria: * drug overdose * opinion of medical team patient unlikely to survive more than 24 hours (severe concurrent medical illness, dilated and unreactive pupils, etc..) * following verbal commands (md or rn note) once ttm is complete and normothermia is achieved (day 2 or 3; day of admission is hospital day 0). if no ttm is administered, this can be assessed on hospital day 2. * following verbal commands (study team assessment) at time of mri * family planning to wlst at time of enrollment * non english speaker (okay if english not primary language, as long as they can understand it) * permanent contraindication to mri (some kind of implanted metal) * pregnant
efficacy of seroquel in selective serotonin reuptake inhibitors (ssri)-resistant major depressive disorder

Conditions: Major Depressive Disorder

Summary: an open-label, non-comparative, multi-centre, phase ii prospective trial to assess the efficacy of quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (ssris) in ssri-resistant major depressive disorder.


Eligibility criteria:
inclusion criteria: * inform consent * male and female, age between 18 and 65 years. * naïve to any atypical antipsychotic * a diagnosis of major depressive disorder exclusion criteria: * no use of fluvoxamine * patients with a history of bipolar i or ii disorder * diagnosis of psychotic major depression disorder

Keywords: considered entry into the study ssri seroquel quetiapine fumarate antipsychotic
esketamine vs remimazolam for postoperative sleep disturbance and anxiety

Conditions: Sleep Disturbance

Summary: to explore and compare the effects of esketamine and remimazolam on postoperative sleep disturbance in patients undergoing oocyte retrieval

postoperative sleep disturbance (psd) occur in the form of sleep deprivation, circadian rhythm disturbance, and structural abnormalities, and have a high incidence in patients undergoing surgery. postoperative sleep disorders can lead to postoperative delirium and cognitive dysfunction, aggravate postoperative acute pain, and delay postoperative recovery. benzodiazepines have a certain sedative hypnotic anti-anxiety effect, and remimazolam as a new benzodiazepine, its sedative hypnotic anti-anxiety effect is worthy of further exploration. esketamine is an n-methyl-d-aspartate(nmda) receptor antagonist with analgesic and sedative effects, and is widely used in clinical treatment of refractory depression. for patients undergoing surgery, in addition to sedation and analgesia, whether the intraoperative use of esketamine has positive effects on postoperative sleep disturbance is worth exploring.

Eligibility criteria:
inclusion criteria: 1. age 18-45 years old; 2. american society of aneshesiologists（asa）physical status classification system is grade i-iii; 3. elective surgery is proposed 4. bmi of 19-30 kg/m2; 5. patients who agreed to enroll in this study voluntarily exclusion criteria: 1. those who are known to be allergic to the drug ingredients in this study and their allergic constitution; 2. allergic history of general anesthesia drugs, opioid drugs, non-steroidal drugs; 3. history of neurological diseases; history of chronic pain; drug and alcohol addiction; a long history of opioid use; opiates were given 48 hours before surgery 4. coronary heart disease, bronchial asthma, severe hypertension, severe blood system dysfunction, liver and kidney function, electrolyte abnormalities; 5. respiratory insufficiency, respiratory failure; 6. bmi\ 30kg/m2; 7. poor compliance, unable to complete the experiment according to the study plan; participants who have participated in clinical trials of other drugs within the last 4 weeks; 8. preoperative pittsburgh sleep quality index (psqi) higher than 7 9. any circumstances deemed unsuitable for inclusion by the researcher for any reason.

Keywords: esketamine remimazolam oocyte retrieval
study of irinotecan & capecitabine in metastatic colorectal cancer

Conditions: Colorectal Neoplasms; Secondary; Drug Therapy, Combination

Summary: this study is to evaluate the efficacy and safety of combination chemotherapy with irinotecan and capecitabine in previously untreated metastatic colorectal cancer.

this is a single center, single arm, open-label, phase ii study to evaluate the efficacy and safety of combination chemotherapy with irinotecan and capecitabine in previously untreated metastatic colorectal cancer. patients younger then 65 will be treated with irinotecan 100 mg/m2 on day 1 and 8 and capecitabine 1,000mg/m2 twice daily from day 1 to 14 every 3 weeks.for patiens equal to or older then 65, doses of irinotecan and capecitabine will be reduced to 60 mg/m2 and 750 mg/2, respectively. response assessment will be performed every 3 cycles of chemotherapy.

Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic colorectal cancer * ecog performance status 0-2 * mesurable lesions * no prior chemotherapyk or radiotherapy for metastatic disease. prior radiotherapy is permitted if it was not administered to target lesions selected for this study and provided it has been completed at least 4 weeks before registration * adjuvnat chemo or radiotherapy was completed at least 6 months prior to start study treatment * adequate organ functions * expected survival is longer then 6 months * informed consent exclusion criteria: * prior systemic chemotherapy for metastatic disease * prior treatment with oxaliplatin or irinotecan * cns metastases * uncontrolled or severe cardiovascular disease * serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy * other malignancy within the past 3 years except cured non-melanomatous skin cancer or carcinoma in situ of the cervix * psychiatric disorder or uncontrolled seizure that would preclude compliance * pregnant, nursing women or patients with reproductive potential without contraception * patients receiving a concomitant treatment with drugs interacting with capecitabine such as flucytosine, phenytoin, or warfarin et al. * prior unanticipated severe reaction to fluoropyrimidine therapy, or known dihydropyrimidine dehydrogenase (dpd) deficiency * major surgery within 3 weeks prior to study treatment starts, or lack of complete recovery from the effects of major surgery

Keywords: colorectal neoplasms secondary drug therapy, combination irinotecan capecitabine